| __timestamp | Bio-Techne Corporation | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 7890000 |
| Thursday, January 1, 2015 | 119401000 | 14456000 |
| Friday, January 1, 2016 | 140879000 | 19218000 |
| Sunday, January 1, 2017 | 199243000 | 27986000 |
| Monday, January 1, 2018 | 240636000 | 47928000 |
| Tuesday, January 1, 2019 | 264359000 | 96388000 |
| Wednesday, January 1, 2020 | 260583000 | 157743000 |
| Friday, January 1, 2021 | 324951000 | 195293000 |
| Saturday, January 1, 2022 | 372766000 | 237374000 |
| Sunday, January 1, 2023 | 378378000 | 295141000 |
| Monday, January 1, 2024 | 396826000 | 359272000 |
In pursuit of knowledge
In the dynamic world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustainable growth. Bio-Techne Corporation and Blueprint Medicines Corporation, two prominent players, have shown distinct trends in their SG&A expenses over the past decade. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 500%, reflecting strategic investments in growth and innovation. Meanwhile, Blueprint Medicines saw an exponential increase of nearly 3,700% in the same period, highlighting its aggressive expansion strategy. Notably, Bio-Techne's expenses peaked in 2024, while Blueprint's data for that year remains unavailable, indicating potential reporting delays or strategic shifts. These trends underscore the importance of cost management in maintaining competitive advantage and driving innovation in the biotech industry.
Johnson & Johnson or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Johnson & Johnson vs Blueprint Medicines Corporation
AstraZeneca PLC and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Sanofi vs Bio-Techne Corporation
Sanofi or Blueprint Medicines Corporation: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Bio-Techne Corporation or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bio-Techne Corporation or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Ionis Pharmaceuticals, Inc.
Blueprint Medicines Corporation and Evotec SE: SG&A Spending Patterns Compared